retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Eli Lilly infiltrates anti-obesity market

Mostly, glucagon-like-peptide-1 medications are prescribed to people who have: A BMI of 30 or more

The weekly dosing convenience is one reason GLP-1 medications have gained such widespread adoption, with many patients preferring one injection per week to the daily injections that insulin protocols require

Retatrutides effectiveness in both adipose tissue reduction and glycemic control suggests it could be a game-changing therapy for type 2 diabetes and obesity management (McPherson et al., 2023)

..I wrote one-third of the LessWrong posts I've ever written in the last month [3]

Endocrinologia, Diabetes y Nutricion, 64 (5), 278280